Abstract Number: L08 • ACR Convergence 2024
A Phase 2b, Randomized, Double-blind, Placebo-controlled, Dose-ranging and Parallel-group Study to Evaluate the Safety and Efficacy of XG005 in Subjects with Painful Osteoarthritis of the Knee
Background/Purpose: Osteoarthritis (OA) affects 595 million people globally; cases are projected to increase 49-95% for various joints by 2050 as populations age (GBD 2023). OA…Abstract Number: L14 • ACR Convergence 2024
A Withdrawal Study of Colchicine in Behçet Syndrome
Background/Purpose: Previous randomized controlled studies reported conflicting results regarding the effectiveness of colchicine on oral ulcers in Behçet syndrome (BS). A randomized drug discontinuation design…Abstract Number: L15 • ACR Convergence 2024
LEVI-04, a Novel neurotrophin-3 Inhibitor, Substantially Improves Pain and Function Without Deleterious Effects on Joint Structure in People with Knee Osteoarthritis: A Randomized Controlled Phase II Trial
Background/Purpose: There is an urgent need for new therapies to treat OA. Excess neurotrophins (NT) are implicated in OA and other painful conditions. Previous OA…Abstract Number: L16 • ACR Convergence 2024
Dapirolizumab Pegol Demonstrated Significant Improvement in Systemic Lupus Erythematosus Disease Activity: Efficacy and Safety Results of a Phase 3 Trial
Background/Purpose: Dapirolizumab pegol (DZP) is a novel, polyethylene glycol (PEG)-conjugated antigen-binding (Fab') fragment, lacking an Fc domain, that inhibits CD40L signaling. By binding to CD40L,…Abstract Number: 0217 • ACR Convergence 2024
Understanding Treatment Goals and Factors Influencing Decisions About Clinical Trial Participation in Lupus Patients from Diverse Backgrounds
Background/Purpose: With many emerging treatments in development for lupus, clinical trial recruitment has become increasingly difficult. Growing appreciation of patient input into trial design may be of …Abstract Number: 1131 • ACR Convergence 2024
Zasocitinib (TAK-279), a Selective Oral Tyrosine Kinase 2 Inhibitor, Reduces Body Surface Area Involvement in a Phase 2b Trial in Moderate-to-Severe Plaque Psoriasis
Background/Purpose: Zasocitinib (TAK-279) is a highly selective, allosteric, oral inhibitor of tyrosine kinase 2 (TYK2). TYK2 mediates signaling from cytokines involved in the pathogenesis of…Abstract Number: 1542 • ACR Convergence 2024
Efficacy and Safety Results from a Phase 2 Trial of Daxdilimab in Patients with Systemic Lupus Erythematosus
Background/Purpose: SLE, an autoimmune disease affecting multiple organ systems, is characterized by periods of flares and remission. Type I interferon secreted at high levels by…Abstract Number: 1735 • ACR Convergence 2024
High-Intensity Interval Training Outperforms Moderate Exercise in Aerobic Capacity for Recent-Onset Idiopathic Inflammatory Myopathies: A Randomized Controlled Trial
Background/Purpose: Exercise is a recognized adjunctive therapy for patients with idiopathic inflammatory myopathies (IIM), enhancing physical capacity and reducing inflammation. Hitherto, moderate-to-intensive exercise has been…Abstract Number: 2353 • ACR Convergence 2024
Effects of Guselkumab on cDAPSA Disease Activity State and Its Association with Long-Term Radiographic Progression in a Cohort of Patients with Moderately-Highly Active Psoriatic Arthritis: Post Hoc Analyses of Phase 3 Randomized Controlled Studies
Background/Purpose: In the Phase 3 DISCOVER (D)-1 and -2 studies, guselkumab (GUS; IL-23p19-subunit inhibitor) 100 mg every 4 weeks (Q4W) or Q8W significantly improved joint…Abstract Number: 2686 • ACR Convergence 2024
Dose Escalation Safety Study of Brentuximab Vedotin for Diffuse Cutaneous Systemic Sclerosis:Clinical Results and Mechanistic Analysis of Skin and Peripheral Blood Mononuclear Cells
Background/Purpose: Brentuximab vedotin (ADCETRIS®) is a drug antibody conjugate targeting CD30 approved for treatment of Hodgkin’s lymphoma (HL) and other hematologic malignancies. Association of CD30…Abstract Number: 0290 • ACR Convergence 2024
Deucravacitinib Long-term Efficacy Through 4 Years in Week 16 Placebo Crossover Patients in the Phase 3 POETYK PSO-1, PSO-2, and LTE Program
Background/Purpose: Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, is approved in the US, EU, and other countries for treatment of adults with moderate…Abstract Number: 1137 • ACR Convergence 2024
Deucravacitinib, an Oral,Selective,Allosteric Tyrosine Kinase 2 Inhibitor, in Patients WithModerate to Severe Scalp Psoriasis: Efficacy and Safety Results of a Phase 3b/4, Multicenter, Randomized, Double-Blinded, Placebo-Controlled Trial (PSORIATYK SCALP)
Background/Purpose: Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 (TYK2) inhibitor, is approved in the US, EU, and other countries for treatment of adults with…Abstract Number: 1552 • ACR Convergence 2024
Kinetics of Mucocutaneous and Musculoskeletal Responses to Deucravacitinibin Patients with Active SLE in the Phase 2 PAISLEY Trial
Background/Purpose: Deucravacitinib is a first-in-class, oral, selective, allosteric tyrosine kinase 2 (TYK2) inhibitor approved in multiple countries for the treatment of moderate to severe plaque…Abstract Number: 1988 • ACR Convergence 2024
A Randomized, Open-Label Study on the Effect of Nipocalimab on Vaccine Responses in Healthy Participants
Background/Purpose: Nipocalimab is a human IgG1 monoclonal antibody targeting the neonatal Fc receptor (FcRn) that selectively reduces IgG levels without impacting antigen presentation, T- and…Abstract Number: 2355 • ACR Convergence 2024
Efficacy of Risankizumab Across Distinct PsA Phenotypes Identified with Machine Learning Analytics Using Data from Biologic DMARD-Naive Patients in Two Phase 3 Clinical Trials
Background/Purpose: Risankizumab (RZB), an IL-23 p19 inhibitor, is well tolerated and provides long-term efficacy through 100 weeks in adults with PsA, demonstrated by the phase…
- 1
- 2
- 3
- …
- 19
- Next Page »